Cohere Health: AI in Prior Authorization & Company Profile

Cohere Health is a fast-growing healthcare technology company (founded circa 2019–2020 in Boston) that has built an AI-powered clinical intelligence platform to revolutionize prior authorization (PA) and utilization management for health plans and providers. The company’s solutions automate both payer and provider workflows, shifting PA from a bureaucratic hurdle to a value-added component of the care journey (^[1]) (^[2]). Using clinician-crafted AI models and evidence-based care guidelines, Cohere’s platform enables up to 90% of authorization requests to be approved automatically and processes millions of PA requests annually (^[3]) (^[4]). In a joint 2022 announcement, Cohere and Geisinger Health Plan reported ~15% incremental medical savings and a 63% reduction in denial rates for the program; the announcement does not independently establish that Cohere caused those results (^[5]) (^[6]). Cohere and its partners also report efficiency metrics, including 70% faster care delivery, 40–55% less provider time on PA, and 93–98% satisfaction (^[7]) (^[5])). These company- and partner-reported figures do not independently establish causal effects at scale. Cohere has attracted top investors and won industry awards for its “next-generation” approach: in May 2025 it closed a $90 million Series C (led by Temasek) bringing total funding to ~$200 million (^[8]), and in September 2025 acquired ZignaAI to expand into payment integrity (^[9]). In 2022 a Cohere–Humana–provider partnership won a KLAS ”Points of Light” award for transforming the PA process (^[10]) (^[11]). In January 2026, Cohere reported record 2025 growth, closing 10 new deals and expanding its platform into acute inpatient care, payment integrity, and policy management (^[12]).

This report analyzes Cohere Health’s origins, strategy, products, and publicly reported results. It covers the U.S. prior-authorization context, the company’s growth, its solution suite, market context, and future directions. Sources include regulatory materials, industry reporting, and Cohere and partner announcements; company- and partner-reported performance figures are identified as such and are not independent causal evaluations.

The U.S. healthcare system has become notorious for cumbersome prior authorization processes, which require clinicians to obtain insurer approval before many tests, prescriptions, and procedures. According to surveys by the American Medical Association (AMA) and specialty societies, the vast majority of physicians (over 90%) report that PA delays care and increases administrative costs (^[13]). For example, an AMA news release in August 2024 found “nearly 90% of physicians surveyed reported that prior authorization leads to higher overall utilization of healthcare resources”, with the result that 69% saw ineffective initial treatments, 68% extra office visits, 42% more emergency visits, and 29% hospitalizations as a consequence (^[13]). In other words, PA bottlenecks can worsen patient outcomes and ultimately raise costs rather than save them (^[13]).

These burdens have prompted calls for reform at all levels. Regulators (e.g. the final CMS Interoperability & PA rule, CMS-0057-F) now require health plans to adopt standardized electronic PA workflows (FHIR-based APIs), with reporting requirements effective January 1, 2026 and full API implementation mandated by January 1, 2027 (^[14]). Industry groups like AHIP and CMS jointly pledged in mid-2025 to accelerate PA modernization across all major plans (^[15]) (^[16]). Nonetheless, fully automating PA is complex: it involves translating clinical policies into machine-readable form, integrating with diverse electronic health record (EHR) systems, and ensuring that evidence-based care guidelines guide decisions. Many existing “robotic” PA solutions simply streamline paperwork or fill forms, but leave major clinical and administrative impediments in place.

Cohere Health emerged to address these challenges by reimagining PA as a collaborative care-management tool rather than a gatekeeping chore (^[1]) (^[10]). Its founders observed that traditional PA is reactive and siloed, requiring separate interactions for each step of a patient’s treatment path. Cohere instead builds “episode-of-care” authorizations: the platform can pre-approve an entire course of treatment (e.g. from diagnostic workup through surgery and rehabilitation) in one integrated workflow (^[17]). The goal is to align patients, providers, and payers on an optimal care plan – delivering the “right care, at the right time, in the right place, and with the right value” (^[18]) (^[19]). In doing so, Cohere leverages AI to automate the bulk of routine decisions (up to 90% auto-approval rates (^[3])) while reserving human oversight for complex cases. This clinician-led, responsible-AI approach has been described by Cohere’s CEO as key to “bringing real clinical intelligence to the table”, differentiating its solution from purely rules-based or “patchwork” systems (^[20]).

Below, we trace Cohere’s growth from a startup to a provider of AI-driven utilization management (UM) tools. We then examine its product suite, contrast its services with legacy approaches, and distinguish company-reported metrics from independently published evidence.

Founding and Management. Cohere Health was co-founded around 2019–2020 by Siva Namasivayam, a healthcare technology veteran (former founder/CEO of SCIO Health Analytics, which was acquired for ~$240M (^[21])). Namasivayam serves as Cohere’s CEO and co-founder (^[22]). His vision – as he has recounted in interviews – was to apply modern analytics and collaboration to end the adversarial PA dynamic. Under his leadership and with input from a medical advisory board, the company developed its first platform (initially called CohereNext or Cohere Unify) and began pitching it to payers in 2020, starting with a focus on complex specialties (e.g. musculoskeletal care) where clear clinical guidelines exist (^[17]) (^[23]).

Funding Rounds. Cohere has raised multiple rounds of private financing to fuel growth. In early 2021 (less than a year after its launch), Cohere closed a $36 million Series B round led by Polaris Partners (with participation from Flare Capital, Longitude, Deerfield, etc.) (^[24]). This followed a smaller Series A in 2020 (at least $10M, including an extension) (^[25]). The capital enabled Cohere to expand its engineering and clinical staff (from under 10 employees in Jan 2020 to over 700 by 2024 (^[26])) and to deepen partnerships with health plans. Additional growth rounds followed: in February 2024 Cohere announced a $50M equity raise (led by Deerfield Management) to meet surging demand under the new CMS PA rule (^[27]). Most recently, in May 2025 Cohere closed a $90M Series C led by Temasek (Singapore’s sovereign fund), bringing total funding to roughly $200M (^[8]). Altogether the company has raised on the order of two hundred million dollars in venture capital, underscoring investor confidence in its model. (Investors have cited Cohere’s unique embedding of clinical expertise in PA automation as a key differentiator (^[20]) (^[28]).)

Key Partnerships and Alliances. Cohere has forged notable strategic partnerships to validate and expand its offerings. In late 2020, Humana announced a collaboration to use Cohere’s platform for musculoskeletal treatments in 12 states, covering ~2 million members and 3,500 physician practices (^[29]) (^[30]). This pilot pre-authorized entire “episodes” (e.g. knee surgeries) rather than isolated procedures – an early proof of concept for Cohere’s model. In mid-2022, Geisinger Health Plan (a Pennsylvania insurer covering >500,000 members) adopted Cohere to support its value-based care program (^[31]). A joint press release highlighted that Cohere’s system would provide “evidence-based, proactive care suggestions” to providers, reducing hand-offs and denials on the way. In October 2024, Cohere and MCG Health announced plans to integrate MCG care guidelines into Cohere’s Unify Decisioning automation tool for prior-authorization workflows (^[32]).

Industry Recognition. Cohere has rapidly earned recognition in the health IT community. In mid-2022 the KLAS research group awarded Cohere (in conjunction with Humana and provider partners) a ”Points of Light” award for a PA collaboration that “reduced the burden of prior authorization and sped patient access to quality care” (^[33]) (^[10]). Reviewers particularly cited Cohere’s elimination of unnecessary pre-approvals and streamlined workflows for top-performing providers (^[11]). The company has also been named among top health-tech startups (e.g. a LinkedIn “Top 5 Startup” in digital health) and appears in analyst reports (e.g. Gartner Hype Cycle for U.S. Healthcare Payers, four consecutive years 2022–2025) (^[34]) (^[35]). In 2025, Cohere was named to TIME’s World’s Top HealthTech Companies, the Inc. 5000 list, ranked No. 218 on the Deloitte Technology Fast 500 (^[36]), and received HLTH 2025’s Best in Class Award for AI (^[12]). These accolades reinforce Cohere’s status as a category innovator.

Timeline of Major Events: The table below summarizes Cohere’s growth milestones and funding:

Year	Event / Milestone	Details
2019–2020	Founding (Boston) (official launch)	Founded by Siva Namasivayam and team to apply AI/analytics to prior auth.
Oct 2020	Humana Partnership (MSK program)	CohereNext platform used for musculoskeletal PA across 12 states (~2M members) ([29]).
Apr 2021	Series B ($36M)	Led by Polaris Partners; new investors include Longitude, Deerfield, etc. ([24]).
Jul 2022	Geisinger Health Plan Deployment	Cohere’s platform adopted to advance value-based care; pilot showed cost savings ([37]).
May 2022	KLAS Points of Light Award	Awarded for joint Humana/Cohere/provider PA collaboration (automated PA) ([10]) ([11]).
Feb 2024	$50M equity raise	Led by Deerfield; total funding reached ~$106M ([27]).
Oct 2024	Cohere–MCG Partnership	Integration with MCG’s clinical criteria to enhance PA decisioning.
Jan 2025	Cohere Connect™ launched	API suite to meet CMS FHIR-based PA rule; supports digital PA submission (6M+ submissions) ([38]).
Mar 2025	Cohere Align™ launched	Personalized PA solution targeting “trusted” providers with streamlined workflows; early results: 80% submissions streamlined, 98% provider satisfaction ([7]).
May 2025	Series C ($90M)	Led by Temasek; total funding ~$200M; will expand AI platform and add use cases ([8]).
Sep 2025	ZignaAI Acquisition	Acquired ZignaAI to expand into AI-powered payment integrity; launched PI Suite with Cohere Validate™ ([9]).
Nov 2025	Deloitte Fast 500 (#218)	Ranked No. 218 on Deloitte Technology Fast 500 based on triple-digit revenue growth ([36]).
Jan 2026	Record 2025 Growth Reported	10 new deals closed; expanded into acute inpatient care, payment integrity, and policy management; 15M+ PA submissions via Connect APIs ([12]).

Cohere’s offerings center on a unified platform that combines AI, analytics, and human review. Its current navigation includes utilization management, payment integrity, appeals, care management, claims operations, and quality. Cohere Unify is the company’s underlying platform; its current offerings span utilization-management workflows, payment integrity, and adjacent clinical and operational functions. Key components and products discussed below include:

• AI-powered Prior Authorization Automation: This is Cohere’s core offering. It includes real-time processing of PA requests, automated decision support, and clinician-assisted approvals. Cohere describes its utilization-management offering as combining clinically trained AI, specialty- and business-rule configuration, and clinical review. Its delegated UM service accepts submissions through phone, fax, EMR, and the Cohere application; Cohere says nurses and physicians conduct clinical reviews and same-specialty physicians make denial determinations. Notable features:

• Auto-approval: Cohere reports that its clinically trained AI can support auto-approval rates of up to 90%; the result is a company-reported operational metric (^[3]). Cohere CEO Siva Namasivayam told Fierce Healthcare that no prior-authorization request is denied exclusively by AI and that clinicians provide final sign-offs for requests requiring review (^[4]).

• Episode-of-care approach: Instead of separate approvals for each procedure, Cohere can pre-authorize an entire care path (e.g. tests, surgery, rehab) in one workflow (^[17]).

• Provider guidance: Cohere describes workflow suggestions and prompts based on clinical guidance that are intended to support providers before submission. In a joint Cohere–Geisinger announcement, the organizations reported a 15% incremental medical-savings result for the program; the announcement does not independently establish that the platform caused that result (^[5]).

• Delegated Utilization Management (“Cohere Complete” for UM): Cohere can take over a health plan’s UM operations entirely. In this model, Cohere’s team of RNs/MDs and AI tools manage end-to-end PA for select specialties. Cohere reports that this delegated service achieved >50% fewer denials overturned on appeal (since requests were more complete) and up to $4.56 PMPM savings on medical benefit expenses in a national cardio UM program (^[39]). Cohere reports 93% provider satisfaction and 96% digital adoption for Cohere Complete, with providers spending 40% less time on authorizations (^[40]).

• Prior Authorization Personalization (Cohere Align™): Launched in 2025, Cohere Align is a “smart waiver/green-lighting” solution that personalizes the PA process. By analyzing providers’ historical behavior and performance, it identifies trusted clinicians (for example, those who consistently follow guidelines) and dynamically adjusts their PA requirements. According to Cohere’s press release, this approach resulted in ~80% of PA submissions being streamlined for pre-approved providers (with minimal extra steps), cutting provider submission time by 55%, and yielding a 98% provider satisfaction score (^[7]). Importantly, Align keeps doctors in the loop; rather than issuing blanket waivers, it delivers tailored prompts and dashboards so that high-volume providers can focus on patient care (aligning with demands for better provider experience (^[41]) (^[7])).

• Interoperability APIs (Cohere Connect™): To support CMS-regulated payers’ applicable interoperability requirements and improve end-user experience, Cohere introduced Cohere Connect in 2025. This is a suite of FHIR®-standard APIs (Coverage Requirements Discovery, Documentation Templates/Rules, and PAS APIs) that allow providers to initiate PAs directly from their EHRs (^[38]). Cohere claims these APIs have already supported over 15 million PA submissions, with workflow-based guidance (e.g. web forms and SMART-on-FHIR integration) to help providers submit complete information (^[38]) (^[42]). The goal is seamless EMR-to-payer transmission of authorization requests, minimizing duplicate data entry. The press release notes that Cohere achieved ~96% digital adoption of its platform (i.e. nearly all transactions through electronic channels) and a provider NPS of 64 (^[43]).

• Payment Integrity / Claim Audit Solutions: Beyond PA, Cohere offers products to modernize claim audit and payment integrity. This capability was significantly strengthened in September 2025 when Cohere acquired ZignaAI, an AI-driven payment integrity and revenue optimization firm founded in 2020, to bridge the gap between utilization management and claims processing (^[9]). The acquisition anchored the launch of Cohere’s full Payment Integrity Suite. The Cohere Validate™ product is an AI-driven audit tool for in-house use: it scans claims and medical records to flag high-risk cases and automate complex audits. Cohere reports that Validate can yield up to $96 per member per year (PMPY) in recoveries in the first year of deployment, with a 14% higher hit rate on audit findings compared to traditional methods, and delivers an 8x ROI for health plans (^[44]) (^[12]). Specialized capabilities include a 58% findings rate for sepsis audit agents. For plans that outsource audits, Cohere Complete for PI provides end-to-end managed services. This service combines Cohere’s AI triage with expert coding audits and appeals. According to Cohere, the outsourced PI service delivered a 30% increase in auditor efficiency vs. legacy vendors, along with high provider satisfaction due to a consultative rather than punitive approach (^[45]). Another component, Cohere Match, reconciles claims against authorizations to identify mismatches before payment.

In summary, Cohere’s product suite spans the full authorization and auditing lifecycle: from initial request intake (via Connect APIs or other submissions), through real-time AI review, to peer-to-peer appeals and audit. The platform is powered by extensive clinical content (e.g. specialty-specific guidelines and evidence) and machine learning models fine-tuned to each plan’s policies. The table below lists key offerings and their roles:

Cohere Offering	Category	Core Function / Impact
Cohere Unify (Platform)	Core Technology	Central platform integrating AI, analytics, & workflow for all solutions.
Cohere Complete (UM Outsourced)	Utilization Management	Fully delegated PA/UM service (RNs/MDs + AI), reducing denials and costs (15%+ med savings) ([5]) with provider satisfaction ~93%.
Cohere Next (Prior Auth AI)	Prior Authorization	Prior-authorization workflow and decisioning capabilities, including episode-based approvals and Connect interoperability. Cohere reports auto-approval rates of up to 90%; this is a company-reported operational metric ([3]) ([42]).
Cohere Align (PA Personalization)	Prior Authorization	Personalized workflow for select providers. Cohere reports that ~80% of requests were streamlined and provider satisfaction was 98%; these are company-reported results ([7]).
Cohere Connect (APIs)	Interoperability	FHIR APIs for PA (CRD, DTR, PAS) enabling digital PA submissions; >15M submissions handled ([12]).
Cohere Review Assist™	Utilization Management	AI-assisted acute inpatient authorization; 50% faster completion ([12]).
Cohere Policy Studio™	Policy Management	AI-powered clinical policy management tool for health plans ([12]).
Cohere Validate (Audit AI)	Payment Integrity (Tools)	AI-driven coding/clinical audit for in-house teams: up to $96 PMPY savings, +14% hit rate ([44]).
Cohere Complete (PI Outsourced)	Payment Integrity (Service)	End-to-end audit service (Cohere coders + AI): 30% faster audits, high efficiency ([45]).
Cohere Match (Reconciliation)	Payment Integrity (Tool)	Reconciles claims against authorization records to identify mismatches before payment.

Clinical and Financial Impact: In its July 2022 joint announcement with Geisinger Health Plan, Cohere reported average 15% incremental medical savings and a 63% reduction in denial rates in its focused program (^[5]). The announcement also reported digital submission rates of up to 95%, immediate approvals that expedited access to care by 70%, and an 18% decrease in surgical complication rates (^[6]). These company-reported figures are not independent evidence that the platform caused the stated outcomes. A KLAS analysis of Cohere’s Humana pilot also noted that shifting many procedures from inpatient to outpatient settings contributed to improved outcomes (^[11]) – a hallmark of higher-value care.

For providers, direct feedback has been overwhelmingly positive. Cohere cites an aggregate 93–98% provider satisfaction across its deployments (^[46]) (^[7]). In practice, clinicians saved significant time: one report showed a 40–55% reduction in physician time spent on PA tasks when using the Cohere system (^[47]) (^[7]). In a broader industry survey conducted by Cohere, 99% of physicians and 96% of office staff said they “trust AI when used appropriately” in PA decision-making (^[48]). This suggests that Cohere’s clinician-centric design (with human oversight and transparent logic) achieves buy-in from users.

Cohere reported in January 2026 that its Connect APIs had supported more than 15 million prior-authorization submissions; this is a company-reported volume metric (^[12]). In a May 2025 interview, CEO Siva Namasivayam said Cohere processed 12 million prior-authorization requests annually and that AI made a real-time decision in 85% of instances, with nurses and physicians providing final sign-offs for the remaining decisions (^[4]). Namasivayam also said that no prior-authorization request is denied exclusively by AI. These are company statements reported by the publication, rather than independent performance evaluations. These efficiencies translate to plan savings; firms like Polaris Partners highlight that Cohere’s technology “fundamentally changes how clinical decisions are made” by aligning evidence and avoiding unnecessary denials (^[28]).

Regulatory and Compliance Outcomes: Cohere’s investments in interoperability support regulatory-readiness efforts. In June 2025, participating insurers made a voluntary industry pledge to standardize electronic prior-authorization submissions using FHIR-based APIs and expand real-time approvals for most requests by 2027; this was not a CMS mandate or a universal API-use requirement. Cohere reports that 85% of prior authorizations are handled in real time and that its systems processed 9 million FHIR-based authorizations in the prior year (^[16]). The same company announcement reports a 61% reduction in provider data-entry time, 50% faster medical-necessity reviews with >99% accuracy, and roughly 94% provider satisfaction across 660,000+ clinicians supported. These are company-reported operational metrics; they do not independently establish Cohere’s leadership, compliance across all applicable CMS requirements, or system-wide progress toward prior-authorization reform.

Competitive Positioning: Cohere’s unique value proposition has been noted by industry analysts. Unlike “touchless” PA solutions that only automate form-filling, Cohere’s clinically intelligent approach has been described as “transformational” (^[28]). Its emphasis on transparency and evidence has earned it top awards and top-tier funding rounds, in a market where other AI startups (e.g. Olive, Redox, etc.) are also active. Importantly, Cohere’s publicly-quoted results (auto-approve rates, satisfaction, savings) are unusually strong: for example, a 93–98% satisfaction rating in healthcare IT is exceptionally high. On the payer side, CFO-level stakeholders have noted Cohere’s “time-to-value” advantage over legacy tech: clients report immediate admin savings and the prospect of medical expense savings (^[1]). These company-reported operational metrics and industry recognitions indicate that Cohere has commercial traction, but they do not by themselves independently validate the platform’s clinical or financial effects.

To illustrate Cohere’s impact “on the ground,” we highlight a few real-world deployments:

• Geisinger Health Plan (Pennsylvania): Cohere partnered with GHP in 2022 to enhance its utilization management across multiple lines (commercial, Medicaid, Medicare Advantage). Public press reports from the joint announcement described strong initial outcomes: the platform ensured PA requests were evidence-based, delivering clinical guidance upfront. As a result, GHP realized ~15% incremental medical savings on these cases and slashed denial rates by 63% (^[5]). The joint announcement reported digital submission rates of up to 95% and stated that immediate approvals expedited patient access by 70% (^[6]). It also reported an 18% decrease in surgical complication rates; the available source does not independently establish that Cohere caused either outcome (^[6]). Geisinger’s Chief Medical Officer praised Cohere for improving both provider experience and alignment with value-based care objectives (^[49]) (^[5]).

• Humana (Musculoskeletal Pilot): In its large PA collaboration, Humana reports that Cohere’s episode-approval model made a “straight line” from diagnosis to recovery for patients (^[50]). By pre-authorizing complete treatment plans, Humana could emphasize conservative therapies and avoid unnecessary escalations. William Shrank, MD, MSHS (Humana Chief Medical Officer and Cohere board member), noted that this co-designed solution “focuses on driving evidence-based, guideline-driven care” while removing administrative obstacles (^[50]) (^[19]). Although detailed metrics from this pilot have not been independently published, the project’s recognition by KLAS (as noted above) indicates measurable spending reductions and provider time savings (^[11]).

• KLAS “Points of Light” Collaboration: KLAS Research described a Cohere-driven PA project (with Humana and providers) that exemplified Cohere’s approach (^[10]). The judges specifically cited improvements in five domains: (1) care quality – for lowering surgical complication rates and shifting procedures to outpatient settings; (2) patient experience – for enabling faster access to care; (3) efficiency – for reducing documentation and admin burden for payers; (4) provider experience – for minimizing peer-to-peer reviews and PA workload; and (5) financial results – for generating medical expense savings (^[11]). This accolade recognizes the collaboration and its reported outcomes, but it does not independently establish that Cohere’s technology caused improvements in care, experience, or cost.

In brief, these cases describe how Cohere and its partners position the platform: through automated approvals, digital workflows, and episode-based authorization. The available sources include company and partner materials and do not independently establish that Cohere caused faster treatment, lower utilization, lower spending, or better clinical outcomes. Provider-experience claims should likewise be read as reported feedback rather than universal results.

Cohere Health’s trajectory reflects broader trends in healthcare and AI. Its success highlights that prior authorization can be transformed through technology and collaboration. Regulatory momentum (CMS rules, state reforms, AMA lawsuits) is pushing payers toward digital, evidence-based PA. Cohere’s clinician-centric AI approach is well-aligned with these forces. As noted by health IT experts and investors, unlike one-size-fits-all AI, Cohere’s solutions are “fine-tuned by medical specialty and business rules” with board-certified doctors in the loop (^[51]) (^[48]). This has earned trust: in a Cohere survey, virtually all doctors (>99%) expressed confidence in AI’s role as long as it remains a support tool (^[48]).

Looking ahead, Cohere says it has expanded its clinically trained, agentic-AI capabilities. The company describes these capabilities as supporting workflows beyond outpatient utilization management; the available company announcement does not independently verify the underlying technical implementation or clinical-reasoning performance (^[12]). The company has already acted on its acquisition strategy: the ZignaAI acquisition in September 2025 expanded Cohere’s domain into payment integrity, and executives have signaled continued interest in broadening through strategic acquisitions (^[52]). New products launched in 2025 – including Cohere Review Assist™ for acute inpatient care (enabling 50% faster authorization completion) and Cohere Policy Studio™ for AI-powered policy management – demonstrate the platform’s expansion well beyond outpatient PA into the broader clinical operations stack.

Cohere reported that it expanded its offerings during 2025 into acute inpatient care, payment integrity, and policy management (^[12]). The announcement identifies Review Assist, the Payment Integrity Suite, and Policy Studio as offerings in those areas, but does not establish that they use one shared technical engine or that they produce treatment-pattern or outcome analytics.

However, challenges remain. Some critics point out that AI models trained on historical data may reinforce existing biases (e.g. underuse in certain populations) unless carefully monitored. Cohere acknowledges this risk by emphasizing transparency and human oversight (^[51]). Another issue is the ongoing reduction of PA requirements announced by major payers. Humana committed to eliminating approximately one-third of outpatient PA requirements by January 1, 2026, removing authorization mandates for services like colonoscopies, select CT scans and MRIs, and launching a new gold card program that waives PA for providers with strong track records (^[53]). Humana also pledged to decide on 95% of complete electronic PA requests within one business day by 2026. While reducing needless PA is positive, the remaining PA tasks are likely to become more focused on clinical nuance – which plays to Cohere’s strengths (highly tailored, clinician-guided AI). Notably, Humana’s gold card model closely mirrors the approach Cohere Align™ already implements.

From the payer’s perspective, Cohere’s model also interacts with payment reform. By delivering “medex savings” that count toward medical loss ratios, Cohere can finance itself as a quality improvement program rather than a fee-per-case vendor (^[40]). This aligns incentives for Medicare Advantage and other value-based payers.

In short, Cohere Health represents an emerging blend of clinical insight, AI technology, and policy awareness. As the healthcare industry increasingly recognizes that the old PA processes are untenable, Cohere’s success suggests a new paradigm: computed collaboration. Rather than battling over authorizations, payers and providers can share data and logic through a platform that makes PA meaningful – driving appropriate care rather than merely checking boxes. Cohere’s published performance figures are company-reported and require independent evaluation before they can support conclusions about the platform’s effects on cost, delays, or clinical outcomes at scale.

Cohere Health has grown from a startup into a provider of AI-powered utilization-management solutions. It has attracted substantial financing and announced partnerships with Humana, Geisinger, and MCG. Cohere’s published Geisinger figures describe reported operational, financial, and clinical outcomes, but the available company and partner materials do not independently establish that Cohere caused those outcomes or validate the model’s effects at scale (^[5]) (^[6]).

Looking forward, Cohere is well-positioned to drive further innovation. The company has rapidly expanded its platform across new domains – from acute inpatient care and payment integrity to policy management – while closing 10 new deals in 2025 alone and earning recognition on TIME's Top HealthTech Companies list, the Inc. 5000, and the Deloitte Fast 500. Its clinician-led approach and early wins are likely to yield continued adoption, especially as health plans face pressure to streamline care and reduce administrative waste. Overall, Cohere Health appears to have successfully “cohered” the three stakeholders of healthcare into a more unified process – and in doing so, set a new standard for how AI and human expertise can jointly improve healthcare delivery (^[2]) (^[11]).

References: This report cites regulatory, industry, company, and news sources, including AMA materials on prior-authorization burdens (^[13]). Data on Cohere’s products and reported performance come primarily from Cohere’s published press releases and webpages (^[8]) (^[27]). Industry recognitions are cited to the available announcement sources (^[10]) (^[35]).